Treatment of cancer in the older aged person

Mediterranean Journal of Hematology and Infectious Diseases

Volumn 2, Issue 2, 2010, Pages

  Balducci, Lodovico ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALOID DERIVATIVE; ANTHRACYCLINE DERIVATIVE; BLEOMYCIN; CYTARABINE; EPOTHILONE DERIVATIVE; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; METHOTREXATE; PLATINUM COMPLEX; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TAXANE DERIVATIVE;

ACUTE GRANULOCYTIC LEUKEMIA; AGE; AGED; AGING; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CARDIOTOXICITY; CAREGIVER; CLINICAL ASSESSMENT; COMPREHENSIVE GERIATRIC ASSESMENT; DOSE CALCULATION; DRUG ABSORPTION; DRUG EFFICACY; DRUG EXCRETION; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; FATIGUE; HUMAN; KIDNEY FUNCTION; LIFE EXPECTANCY; LUNG FIBROSIS; MALIGNANT NEOPLASTIC DISEASE; MUCOSA INFLAMMATION; MYELODYSPLASTIC SYNDROME; NAUSEA AND VOMITING; NEUROTOXICITY; PERIPHERAL NEUROPATHY; REVIEW; SURVIVAL;

EID: 79952753142     PISSN: None     EISSN: 20353006     Source Type: Journal    
DOI: 10.4084/MJHID.2010.029     Document Type: Review

References (50)

1. Yancik R; Ries LA. Cancer in the Older Person: an International issue in an aging world. Sem Oncol, 2004, 31, 128-136
2. Balducci L, Colloca G, Cesari M, et al. Assessment and treatment of elderly patients with cancer. Surg Oncol, 2010, in press
3. Walston J, Hadley EC, Ferrucci L, et al. Research Agenda for frailty in Older Adults. J Am Ger Soc, 2006 54, 991-2001
4. Gruenewald TL, Seeman TE, Karlamangla AS, et al. Allostatic Load and frailty in older individuals. J Am Geriatr Soc. 2009 Sep;57(9):1525-31. Epub 2009 Jul 21.
5. Willeit P; Willeit J; Mayr A et al. Telomere length and incident cancer and Cancer Mortality. JAMA, 2010, 304, 69-75
6. Wong LS, van der Harst P, de Boer RA, et al. Aging, telomeres, and heart failure. Heart Fail Rev. 2010 in press
7. Willeit P, Willeit J, Brandstätter A, et al. Cellular aging reflected by leukocyte telomere length predicts advanced atherosclerosis and cardiovascular disease risk., Arterioscler Thromb Vasc Biol. 2010 30(8):1649-56.
8. Sahin E, Depinho RA. Linking functional decline of telomeres, mitochondria and stem cells during ageing. Nature. 2010 Mar 25;464(7288):520-8
9. Babizhayev MA, Savel yeva EL, Moskvina SN, et al. Telomere Length is a Biomarker of Cumulative Oxidative Stress, Biologic Age, and an Independent Predictor of Survival and Therapeutic Treatment Requirement Associated With Smoking Behavior. Am J Ther. 2010 in press.
10. Risques RA; Arbeev KG; Yashin AI et al. Leukocyte Telomere Length is associated with disability in the older USA population. J Am Ger Soc, 2010, 58, 1289-1298
11. Ferrucci L, Corsi A, Lauretani F, et al. The origin of Agerelated pro-inflammatory state. Blood, 2005, 105, 2294-2299
12. Maggio M, Guralnik JM, Longo DL, et al. Interleukin-6 in aging and chronic disease: a magnificent pathway. J Gerontol A Biol Sci Med Sci. 2006 Jun;61(6):575-84
13. Crimmins E, Vasunilashorn S, Kim JK, et al. biomarkers related to aging in the human population. Adv Clin Chem. 2008; 46, 161-216
14. Gurven M, Kaplan H, Winking J, Finch C, Crimmins EM. aging and inflammation in two epidemiological worlds. J Gerontol A Biol Sci Med Sci. 2008 Feb;63(2):196-201
15. Extermann M; Hurria A. Comprehensive Geriatric Assessment in older patients with cancer. J Clin Oncol, 2007, 25, 1824-1831
16. Luciani A, Ascione G, Bertuzzi C, et al. Detecting disabilities in older patients with cancer: comparison between comprehensive geriatric assessment and vulnerable elders survey-13. J Clin Oncol. 2010 Apr 20;28(12):2046-50
17. Brunello A, Sandri R, Extermann M. Multidimensional geriatric evaluation of the older cancer patient as a clin Cancer treat Rev, 2009, 35, 487-492
18. Störk S, Feelders RA, van den Beld AW, et al. Prediction of mortality risk in the elderly. Am J Med. 2006 Jun;119(6):519-25
19. Carey EC, Covinsky KE, Lui LY, et al. Prediction of mortality in community-living frail elderly people with longterm care needs. J Am Geriatr Soc. 2008 Jan;56(1):68
20. M. Extermann, I. Boler, R. Reich, et al. The Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score: Design and validation.. ASCO national conference 2010, Abstr 9000
21. A. Hurria, K. Togawa, S. G. Mohile, et al. Predicting chemotherapy toxicity in older adults with cancer: A prospective 500 patient multicenter study. ASCO Proc, 2010, Abstr 9001
22. Extermann M. Interactions of Cancer and Comorbidity. Cancer Control, 2007, 14, 13-22
23. Kulminski AM, Ukraintseva SV, Kulminskaya IV, et al. Cumulative deficits better characterizes susceptibility to death in elderly people than phenotypic frailty. Lessons from the Cardiovascular Health Study. J Am Ger Soc, 2008, 56, 898-903
24. Pal SK, Hurria A. Impact of age, sex, and comorbidity on cancer treatment and disease progression J Clin Oncol. 2010 Jul 19.
25. Klepin H, Mohile S, Hurria A. Geriatric assessment in Older patients with Breast Cancer. J Natl Compr Canc Netw. 2009 Feb;7(2):226-36
26. Ferrucci L and Balducci L. Anemia of aging: role of chronic inflammation and cancer. Semin Hematol, 2008, 45, 242-249
27. Haider SI, Johnell K, Weitoft GR et al. The influence of educational level on polypharmacyand inappropriate drug use. A register based study of more than 600000 older people. J Am Ger Soc, 2009, 57, 62-69
28. Maggiore RJ, Gross CP, Hurria A. Polypharmacy in older Adults with Cancer. Oncologist. 2010;15(5):507-22
29. Lee SJ, Lindquist K, Segal MRet al. Development and validation of a prognostic index for 4-year mortality in older adults. JAMA. 2006 Feb 15;295(7):801-8.
30. Carey EC, Covinsky KE, Lui LY, et al.: Prediction of mortality in community-living frail elderly people with longterm care needs. J Am Geriatr Soc. 2008 Jan;56(1):68-75
31. Schonberg MA, Davis RB, McCarthy EP, et al. Index to predict 5-year mortality of community-dwelling adults aged 65 and older using data from the National Health Interview Survey. J Gen Intern Med. 2009 Oct;24(10):1115-22
32. Extermann M; Overcash J; Lyman GH; et al. Comorbidity and performance status are independent in older cancer patients. J Cin Oncol, 1998, 16, 1582-1587
33. Ingram SS, Seo PH, Martell RE, et al. Comprehensive assessment of elderly Cancer patients: the feasiblility of selfreport methodology. J Clin Oncol, 2002, 20, 770-775
34. Repetto L, Fratino L, Audisio RA, et al. Comprehensive Geriatric assessment adds information to Eastern Cooperative Group Performance Status in Elderly Cancer Patients: an Italian Group for geriatric Oncology Study. J Clin Oncol, 2002, 15, 494-502
35. Fried LP, Tangen CM, Walston J, et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci. 2001 Mar;56(3):M146-56
36. Ensrud KE, Ewing SK, Taylor BC, et al. (2008); Comparison of two frailty indices for prediction of falls, disability, fractures, and death in older women. Arch Intern Med, 168, 382-389.
37. Ensrud KE, Ewing SK, Cawthon PM, et al, Cummings SR; Osteoporotic Fractures in Men Research Group (2009): A comparison of two frailty indices for prediciton of falls, disability, fractures and death in older men. J Am Ger Soc, 57, 492-49
38. Searle SD, Mitnitski A, Gahbauer EA, Gill TM, Rockwood K. (2008): A standard procedure for creating a frailty index. BMC Geriatr, 30, 8-24.
39. Xue QL, Bandeen-Roche K, Varadhan R et al Initial Manifestations of frailty criteria and the development of frailty phenotype in the Women Health and Aging Study II. J Gerontol Med Sci 2008, 63, 984-990
40. Carreca I, Balducci L. Cancer chemotherapy in the older cancer patient Urol Oncol. 2009 Nov-Dec;27(6):633-42
41. Lyman GH, Kuderer NM. A primer in prognostic and predictive models: development and validation of neutropenia risk models. Support Cancer Ther. 2005 Apr 1;2(3):168-75.
42. Kuderer NM, Dale DC, Crawford J, et al. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol. 2007 Jul 20;25(21):3158-67.
43. Balducci L, Al Halawani H, Charu V et al. Elderly cancer patients receiving chemotherapy benefit from first-cycle pegfilgrastim. Oncologist. 2007 Dec;12(12):1416-24.
44. Lyman GH, Dale DC, Wolff DA, et al. Acute myeloid leukemia or myelodysplastic syndrome in randomized controlled clinical trials of cancer chemotherapy with granulocyte colony-stimulating factor: a systematic review. J Clin Oncol. 2010 Jun 10;28(17):2914-24. Epub 2010 Apr 12
45. Bohlius J, Schmidlin K, Brillant C, et al. Erythropoietin or Darbepoetin for patients with cancer--meta-analysis based on individual patient data. Cochrane Database Syst Rev. 2009 Jul 8;(3):CD007303. Review.
46. Sonis ST. Regimen-related gastrointestinal toxicities in cancer patients. Curr Opin Support Palliat Care. 2010 Mar;4(1):26-30.
47. Minton O, Richardson A, Sharpe M, et al. A systematic review and meta-analysis of the pharmacological treatment of cancer-related fatigue.J Natl Cancer Inst. 2008 Aug 20;100(16):1155-66.
48. Dy SM, Lorenz KA, Naeim A et al. Evidence-based recommendations for cancer fatigue, anorexia, depression, and dyspnea. J Clin Oncol. 2008 Aug 10;26(23):3886-95
49. Broder H, Gottlieb RA, Lepor NE. chemotherapy and cardiotoxicity Rev Cardiovasc Med. 2008 Spring;9(2):75-8
50. Manton KG, Gu X, Lowrimore GR. Cohort changes in active life expectancy in the U.S. elderly population: experience from the 1982-2004 National Long-Term Care Survey. J Gerontol B Psychol Sci Soc Sci. 2008 Sep;63(5):S269-81.